This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pan African Clinical Trials Registry | |
|---|---|
| Name | Pan African Clinical Trials Registry |
| Formation | 2007 |
| Headquarters | South Africa |
| Region served | Africa |
Pan African Clinical Trials Registry is a regional platform for registration of clinical trials conducted in Africa that aims to improve transparency, accountability, and access to trial information across the continent. It connects investigators, funders, regulators, and publishers by providing a publicly accessible database intended to meet international standards and to facilitate collaboration among research institutions, ethics committees, and health authorities. The registry operates within a landscape shaped by global initiatives and regional health priorities involving numerous research partners and academic centres.
The registry functions as a prospective and retrospective repository aligned with requirements from World Health Organization, International Committee of Medical Journal Editors, ClinicalTrials.gov, European Medicines Agency, African Union health initiatives, and national regulatory agencies such as South African Health Products Regulatory Authority and Nigeria Centre for Disease Control. It accepts trial records from sponsors including academic institutions like University of Cape Town, Makerere University, and University of Nairobi, as well as nongovernmental organizations such as Médecins Sans Frontières and Bill & Melinda Gates Foundation-funded consortia. The platform supports transparency efforts championed by publishers like The Lancet, New England Journal of Medicine, and BMJ, and interacts with ethics review boards at hospitals including Groote Schuur Hospital and Kenyatta National Hospital.
The initiative emerged amid discussions at global forums including World Health Assembly meetings and consultations convened by World Health Organization and Council for International Organizations of Medical Sciences to address underreporting of trials in Africa. Early collaborations involved partners such as South African Medical Research Council, INDEPTH Network, and regional networks like African Academy of Sciences. Milestones include operational launch with technical support from entities like University of Toronto collaborators and methodological guidance influenced by documents from CONSORT authors and advisory input from investigators linked with London School of Hygiene & Tropical Medicine and Harvard School of Public Health.
The registry's purpose is to register interventional and observational studies involving medicinal products, devices, and behavioral interventions conducted in Africa, serving investigators from institutions such as Stellenbosch University, Addis Ababa University, and Kwame Nkrumah University of Science and Technology. Its scope encompasses trials on priority diseases addressed by Roll Back Malaria Partnership, Global Fund to Fight AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance, including work on conditions studied at centres like Ahmadu Bello University and University of Lagos. It supports compliance with publication policies from organizations such as International Committee of Medical Journal Editors and funder mandates from groups like Wellcome Trust and European & Developing Countries Clinical Trials Partnership.
Researchers affiliated with universities, hospitals, contract research organizations such as IQVIA, and pharmaceutical companies submit prospective trial registrations with protocol summaries, investigator lists, and ethical approvals from boards like National Health Research Ethics Council (South Africa) and counterparts in Kenya and Uganda. The process mirrors requirements used by ClinicalTrials.gov and ISRCTN Registry, and data fields are informed by standards promulgated by WHO Trial Registration Data Set and guidance from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Sponsors may include public entities like National Institutes of Health-supported programmes and philanthropic funders such as Wellcome Trust or Gates Foundation-backed initiatives.
Data collection follows metadata and nomenclature approaches rooted in WHO, CONSORT, and ICH recommendations, with curation tasks performed by registry staff and peer reviewers connected to regional research hubs like Institut Pasteur de Dakar and KEMRI. Quality control involves verification of trial identifiers, ethics approvals from committees associated with institutions such as Muhimbili University of Health and Allied Sciences, and cross-checks against registries including European Clinical Trials Register and Pan American Health Organization databases. Harmonization efforts reference standards advanced by CDISC and engage methodological experts from Johns Hopkins Bloomberg School of Public Health and Imperial College London.
Governance structures incorporate advisory input from representatives of research councils like South African Medical Research Council, international agencies such as World Health Organization, and academic partners including University of the Witwatersrand and University of KwaZulu-Natal. Funding has come from multilateral and bilateral sources including World Bank-linked health programmes, philanthropic organisations like Wellcome Trust and Bill & Melinda Gates Foundation, and institutional support from regional universities and ministries of health in nations including South Africa, Kenya, and Nigeria.
The registry has increased visibility of African trials used by systematic reviewers at institutions like Cochrane Collaboration, guideline developers in World Health Organization, and meta-analysts at centres such as Johns Hopkins University. Critics cite challenges familiar to registries worldwide, including incomplete data entry, variable enforcement by national regulators such as National Agency for Food and Drug Administration and Control (Nigeria), and resource limitations affecting curation—issues debated at forums like Global Forum for Health Research and workshops convened by African Union. Calls for improvement reference best practices from ClinicalTrials.gov and European Medicines Agency and demand strengthened ties with publishers such as PLOS and Elsevier to ensure prospective registration and full reporting.
Category:Clinical trial registries Category:Health in Africa